Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications

被引：29

作者：

Anandarajah, AP

Schwarz, EM

机构：

[1] Univ Rochester, Med Ctr, Dept Allergy Immunol & Rheumatol, Rochester, NY 14642 USA

[2] Univ Rochester, Dept Orthoped, Rochester, NY 14642 USA

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2006年 / 97卷 / 02期

关键词：

RANKL; inflammatory bone disease; erosions;

D O I：

10.1002/jcb.20674

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Focal bone lose around inflamed joints in patients with autoimmune disease, such as rheumatoid arthritis, remains a serious clinical problem. The recent elucidation of the RANK/RANK-ligand/OPG pathway and its role as the final effector of osteoclastogenesis and bone resorption has brought a tremendous understanding of the pathophysiology of inflammatory bone loss, and has heightened expectation of a novel intervention. Here, we review the etiology of inflammatory bone loss, the RANK/RANK-lignad/OPG pathway, and the clinical development of anti-RANK-ligand therapy.

引用

收藏

页码：226 / 232

页数：7

相关论文

共 55 条

[1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].

Anderson, DM ;

Maraskovsky, E ;

Billingsley, WL ;

Dougall, WC ;

Tometsko, ME ;

Roux, ER ;

Teepe, MC ;

DuBose, RF ;

Cosman, D ;

Galibert, L .

NATURE, 1997, 390 (6656) :175-179

[2] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[3] The effect of a single dose of osteoprotegerin in postmenopausal women [J].

Bekker, PJ ;

Holloway, D ;

Nakanishi, A ;

Arrighi, M ;

Leese, PT ;

Dunstan, CR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360

[4] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[5] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[6] CHONDROCLASTS AND OSTEOCLASTS AT SUBCHONDRAL SITES OF EROSION IN THE RHEUMATOID JOINT [J].

BROMLEY, M ;

WOOLLEY, DE .

ARTHRITIS AND RHEUMATISM, 1984, 27 (09) :968-975

[7] HISTOPATHOLOGY OF THE RHEUMATOID LESION - IDENTIFICATION OF CELL-TYPES AT SITES OF CARTILAGE EROSION [J].

BROMLEY, M ;

WOOLLEY, DE .

ARTHRITIS AND RHEUMATISM, 1984, 27 (08) :857-863

[8]

Brown JM, 2001, CLIN CANCER RES, V7, P2977

[9] Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].

Browner, WS ;

Lui, LY ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637

[10] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

← 1 2 3 4 5 6 →